来宝网 2012/5/4点击2551次
BIOTRONIKs Lumax 740 系列（照片：美國商業資訊）
BIOTRONIK Lumax 740 ProMRI® ICD亞洲首例植入手術
柏林--(美國商業資訊)--創新醫療科技的領先製造商BIOTRONIK今天宣佈，新款Lumax 740 ICD (植入式心臟除顫器)的首例植入手術在香港完成。Lumax 740是世界首款、也是唯一一款獲准用於磁共振掃描(MRI)的ICD和CRT-D系列1，憑藉BIOTRONIK的創新ProMRI®技術，現在能夠為ICD和CRT-D患者提供接受挽救生命不可或缺的MR掃描的機會。此機型結合了該產品延長的機器壽命和BIOTRONIK Home Monitoring®，使Lumax 740系列位居針對心動過速型心律不整患者的心臟儀器的尖端。
香港港安醫院電生理學實驗室主任馮永康醫生說：「BIOTRONIK在Lumax 740系列中的ProMRI®創新，對於需要ICD的患者是一個重大突破。」Lumax 740 ICD於2012年4月17日在全球上市，之後，馮永康醫生成功完成了亞洲首例Lumax 740 ICD裝置植入手術。
馮醫生說：「我感到高興的是，BIOTRONIK在Lumax 740系列中的ProMRI®創新，最終能造福香港的患者，ICD患者現在能夠受益於這一科技。直到最近，ICD患者還被排除在MR掃描之外，儘管這些掃描對於罹患嚴重內科疾病，如癌症、中風和其他神經系統和骨科疾病的患者的診治至關緊要。」
全球需要ICD的患者人群正在增加，年增率約為10-15%。同時，對MR掃描的需求也在成長，每年成長率約為10%。2006年進行了近3千萬次掃描，2010年全球已進行了約5千萬次MR掃描。2 隨著需要ICD的患者比例攀升和對MR掃描不斷成長的需求，估計ICD患者在其植入裝置的機器壽命期間，將有50-75% 的機率需要接受一次MR掃描。3
新型Lumax 740系列是BIOTRONIK技術先進的心動過速產品陣容的組成部分，包括三種ICD、一種CRT-D裝置和16種導線。經過時間的考驗，Linoxsmart ICD導線的品質和可靠性最高，現在憑藉ProMRI®得到了進一步增強。除了具備ProMRI®技術，該裝置還因擁有最長達11年的機器壽命而領先於業界。
BIOTRONIK總經理Christoph Böhmer評論道：「BIOTRONIK基於強大的發展策略而致力於向亞太市場提供品質和可靠性最高的創新產品，並在該地區樹立有力的市場領導地位。2012年1月我們在新加坡新設了地區總部，BIOTRONIK將全力發揮亞太國家快速發展的優勢，進一步推動公司近年來一直保持的業界領先的成長軌跡。」
BIOTRONIK為一家全球性企業，過去七年來營業額持續以兩位數成長，為員工提供的就業機會也增加一倍，已在亞太地區開創了強勁的業務。
關於 BIOTRONIK Home Monitoring®
自2000年首次應用於臨床以來，BIOTRONIK Home Monitoring® 一直引領著遠端患者管理的進步。該系統獨一無二，因為它可對患者狀況和儀器狀況進行連續的自動化無線遠端監護，每天進行更新，而完全毋需任何患者互動。TRUST4''5標誌性試驗結果證實，該技術可促成及早干預。現今，BIOTRONIK Home Monitoring® 廣泛應用於全球56個國家的5''300多家診所中。
關於 ProMRI®
ProMRI® 使起搏器、ICD或CRT-D患者能夠接受MR掃描。BIOTRONIK ProMRI® 心動過速系列是首款設計、試驗和獲准用於MR掃描的ICD-/CRT-D產品陣容。醫生藉此擁有了獨特的機會，能夠從Lumax 740系列中選用最合適的儀器--為患者提供能同時接受MR掃描的最先進治療。
關於BIOTRONIK SE & Co. KG
BIOTRONIK公司是世界領先的心血管器材公司之一，已植入裝置達數百萬台，全球員工超過5600位，業務遍及100多個國家。BIOTRONIK公司密切感知醫療界的脈動、體味醫生面臨的挑戰，從診斷、治療到患者管理，為患者醫護的所有階段提供最佳解決方案。BIOTRONIK公司及其不斷成功的理念在於品質、創新和臨床卓越，從而為醫生及其患者帶來信心和安心。
進一步資訊，請造訪：www.biotronik.com
參考文獻
1有關ProMRI® 的詳細資訊，包括全套條款和先決條件，請至www.biotronik.com/promri
2 Morgan Stanley'' ICD market'' 1996-2009.
3 Roguin et al.'' Europace 2008'' 10'' 336-346.
4 Varma et al.'' Circulation 2010'' 122'' 325-332.
5 Varma et al.'' Circ Arrhythm Electrophysiol 2010'' 3:428-436.
發佈時，請向我方提供副本。
圖片/多媒體資料庫可以從以下網址獲得：http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50264257&lang=en
免責聲明：本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用，煩請參照原文，原文版本乃唯一具法律效力之版本。
聯絡方式：
亞太區聯絡人
Gunnar Wochnowski
亞太區副總裁
BIOTRONIK Asia Pacific Pte Ltd
Tel.: +65-6631-2895
+61 2 9497 3703
Email: gunnar.wochnowski@biotronik.com
或
全球聯絡人：
Sandy Hathaway
全球傳播部資深總監
BIOTRONIK SE & Co. KG
Tel. +49-(0)-30-68905-1602
Email: sandy.hathaway@biotronik.com
BIOTRONIKs Lumax 740 系列（照片：美國商業資訊）
BIOTRONIK Gives ICD Patients in Asia Pacific First-Ever Access to MR Scans
First Implantation of BIOTRONIK Lumax 740 ProMRI® ICD in Asia
BERLIN, Germany, April 27 2012 – BIOTRONIK a leading manufacturer of innovative medical technology, announced today the first implantation of the new Lumax 740 ICD (implantable cardiac defibrillator) in Hong Kong.Lumax 740 is the world’s first and only ICD and CRT-D series approved formagnetic resonance imaging (MRI)1, now giving ICD and CRT-D patients access to vital MR scans with BIOTRONIK’s innovative ProMRI® technology. This combined with the product’s extended device longevity andBIOTRONIK Home Monitoring®, brings the Lumax 740 series to the forefront of cardiac devices for patients with tachyarrhythmias.
“BIOTRONIK’s ProMRI® innovation in the Lumax 740 series is an important breakthrough for patients needing ICDs,” says Dr. Jeffrey Wing-Hong Fung, Director of Electrophysiology Laboratory at Hong Kong Adventist Hospital. After the international launch on April 17th 2012, the first device implantation of a Lumax 740 ICD in Asia was successfully performed by Dr. Jeffrey Wing-Hong Fung.
“I am glad that BIOTRONIK’s ProMRI® innovation in the Lumax 740 series is finally available to patients in Hong Kong and that ICD patients can now benefit from this technology,” said Dr. Fung. “Until now, patients with an ICD had been excluded from undergoing MR scans despite the fact that these scans are critical for the diagnosis and therapy of patients with serious medical conditions, such as cancer, stroke and other neurologic and orthopaedic conditions.”
Worldwide, the population of patients who need an ICD is growing at a rate of about 10–15 percent annually. At the same time, the need for MR scans is also increasing at a rate of about 10 percent each year. Approximately 30 million scans were performed in 2006, and in 2010, there were already about 50 million MR scans conducted worldwide.2 The soaring rates of patients needing ICDs and the increasing need for MR scans result in an estimated 50–75 percent probability that an ICD patient would be indicated for an MR scan over the lifetime of his or her implanted device.3
The new Lumax 740 series is part of BIOTRONIK´s technologically advanced tachycardia product portfolio, which includes three ICDs, one CRT-D device and 16 leads. The Linoxsmart ICD leads have been proven over time to be of the highest quality and reliability, and are now further enhanced with ProMRI®. Besides featuring ProMRI® technology, the devices also stand out in the industry by providing longevities of up to 11 years.
“BIOTRONIK has a strong strategic commitment to bring innovative products of the highest quality and reliability to the Asia Pacific market and to build a powerful market leadership in the region,” commented Christoph Böhmer, Managing Director BIOTRONIK. “With the opening of our new regional headquarters in Singapore in January 2012, BIOTRONIK will fully leverage the accelerated development of the Asia Pacific countries to further propel the industry-leading growth trajectory that the company has maintained during previous years,” he continued.
As a global enterprise that has achieved consistent double-digit growth in revenue during the last seven years, as well having doubled its job opportunities for employees, BIOTRONIK has built a strong presence in Asia Pacific.
About BIOTRONIK Home Monitoring®
BIOTRONIK has pioneered advances in its BIOTRONIK Home Monitoring®remote patient management system since its first clinical application in the year 2000. The system is unique because it allows continuous, automatic wireless remote monitoring of patient status and device status with daily updates—all independent of any patient interaction. The technology leads to earlier intervention, as proven by the results of the TRUST4,5 landmark trial. Today, BIOTRONIK Home Monitoring® is used extensively in more than 5,300 clinics and 56 countries worldwide.
About ProMRI®
ProMRI® allows patients with a pacemaker, ICD or CRT-D to undergo MR scans. The BIOTRONIK ProMRI® tachycardia series marks the first time an ICD-/CRT-D portfolio has been designed, tested and approved to make MR scans possible. As a result, physicians have the unique opportunity to select the optimal device from the Lumax 740 series—offering their patients the most advanced therapy available along with access to MR scans.
About BIOTRONIK SE & Co. KG
As one of the world’s leading cardiovascular medical device companies, with several million implanted devices, BIOTRONIK is represented in over 100 countries with its global workforce of more than 5,600 employees. Known for having its fingers on the pulse of the medical community, BIOTRONIK assesses the challenges physicians face and provides the best solutions for all phases of patient care, ranging from diagnosis and treatment to patient management. Quality, innovation and clinical excellence define BIOTRONIK and its growing success—and deliver confidence and peace of mind to physicians and their patients worldwide.
For more information: www.biotronik.com
References
1 For detailed information about ProMRI® including the complete set of conditions and prerequisites please visit www.biotronik.com/promri
2 Morgan Stanley, ICD market, 1996–2009.
3 Roguin et al., Europace 2008, 10, 336–346.
4 Varma et al., Circulation 2010, 122, 325–332.
5 Varma et al., Circ Arrhythm Electrophysiol 2010, 3:428–436.
